Article
BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $15
BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $55 to $15.
Comments
- No comments yet. Be the first to comment!